Bevacizumab (including biosimilars of bevacizumab): Drug information
Copyright 1978-2018 Lexicomp, Inc. All rights reserved.
(For additional information see "Bevacizumab (including biosimilars of bevacizumab): Patient drug information" and see "Bevacizumab (including biosimilars of bevacizumab): Pediatric drug information")

For abbreviations and symbols that may be used in Lexicomp (show table)
ALERT: US Boxed Warning
GI perforations:

The incidence of GI perforations, some fatal, in patients receiving bevacizumab products ranges from 0.3% to 3%. Discontinue bevacizumab products in patients with GI perforation.

Surgery and wound healing complications:

The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in patients receiving bevacizumab products. Discontinue bevacizumab products in patients who develop wound healing complications that require medical intervention. Withhold bevacizumab products at least 28 days prior to elective surgery. Do not administer bevacizumab products for at least 28 days after surgery and until the surgical wound is fully healed.

Hemorrhage:

Severe or fatal hemorrhage, including hemoptysis, GI bleeding, hematemesis, CNS hemorrhage, epistaxis, and vaginal bleeding, occurs up to 5-fold more frequently in patients receiving bevacizumab products. Do not administer bevacizumab products to patients with a recent history of hemoptysis. Discontinue in patients who develop grade 3 to 4 hemorrhage.

Brand Names: US
  • Avastin
Brand Names: Canada
  • Avastin
Pharmacologic Category
  • Antineoplastic Agent, Monoclonal Antibody;
  • Antineoplastic Agent, Vascular Endothelial Growth Factor (VEGF) Inhibitor;
  • Vascular Endothelial Growth Factor (VEGF) Inhibitor
Dosing: Adult

Note: Do not administer bevacizumab products until at least 28 days after surgery and the wound is fully healed.

Cervical cancer, persistent/recurrent/metastatic (Avastin [bevacizumab], Mvasi [bevacizumab-awwb; biosimilar]): IV: 15 mg/kg every 3 weeks (in combination with paclitaxel and either cisplatin or topotecan) until disease progression or unacceptable toxicity (Tewari 2014)

Colorectal cancer, metastatic, in combination with fluorouracil-based chemotherapy (Avastin, Mvasi): IV: 5 mg/kg every 2 weeks (in combination with bolus-IFL) or 10 mg/kg every 2 weeks (in combination with FOLFOX4)

Colorectal cancer, metastatic, following first-line therapy containing bevacizumab (Avastin, Mvasi): IV: 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks (in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based regimen)

Glioblastoma, recurrent or progressive (Avastin, Mvasi): IV: 10 mg/kg every 2 weeks as a single agent until disease progression or unacceptable toxicity or (off-label combination) 10 mg/kg every 2 weeks (in combination with irinotecan) until disease progression or unacceptable toxicity (Friedman 2009; Vredenburgh 2007)

Non-small cell lung cancer (nonsquamous cell histology), first-line therapy (Avastin, Mvasi): IV: 15 mg/kg every 3 weeks (in combination with carboplatin and paclitaxel) for 6 cycles (Sandler 2006)

Off-label combinations: 15 mg/kg every 3 weeks (in combination with pemetrexed and carboplatin) for up to 4 cycles (Patel 2013) or 7.5 or 15 mg/kg every 3 weeks (in combination with cisplatin and gemcitabine) for up to 6 cycles (Reck 2009; Reck 2010) or 7.5 mg/kg every 3 weeks (in combination with pemetrexed and cisplatin) for 4 cycles (Barlesi 2013)

Maintenance therapy (off-label use): 15 mg/kg every 3 weeks as a single agent (after 6 cycles of induction therapy with bevacizumab, carboplatin and paclitaxel); continue maintenance therapy until disease progression or unacceptable toxicity (Sandler 2006) or 15 mg/kg (in combination with pemetrexed) every 3 weeks (following 4 cycles of induction therapy with bevacizumab, pemetrexed, and carboplatin); continue until disease progression or unacceptable toxicity (Patel 2013) or 7.5 mg/kg (in combination with pemetrexed) every 3 weeks (following 4 cycles of induction therapy with bevacizumab, cisplatin and pemetrexed); continue until disease progression or unacceptable toxicity (Barlesi 2013)

Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-resistant recurrent) (Avastin): IV: 10 mg/kg every 2 weeks (in combination with weekly paclitaxel, every 4 week doxorubicin [liposomal], or days 1, 8, and 15 topotecan) or 15 mg/kg every 3 weeks (in combination with every 3 week topotecan) (Pujade-Lauraine 2014)

Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-sensitive recurrent) (Avastin): IV: 15 mg/kg every 3 weeks (in combination with carboplatin and gemcitabine for 6 to 10 cycles or with carboplatin and paclitaxel for 6 to 8 cycles) then continue with bevacizumab (monotherapy) until disease progression or unacceptable toxicity (Aghajanian 2012; Aghajanian 2015; Coleman 2015).

Renal cell cancer, metastatic (Avastin, Mvasi): IV: 10 mg/kg every 2 weeks (in combination with interferon alfa) or (off-label dosing) 10 mg/kg every 2 weeks as monotherapy (Yang 2003)

Age-related macular degeneration (off-label use/route): Intravitreal: 1.25 mg (0.05 mL) monthly for 3 months, then may be given scheduled (monthly) or as needed based on monthly ophthalmologic assessment (Chakravarthy 2013; Martin 2012)

Breast cancer, metastatic (off-label use): IV: 10 mg/kg every 2 weeks (in combination with paclitaxel) (Miller 2007)

Diabetic macular edema (off-label use/route): Intravitreal: 1.25 mg (0.05 mL) initially; repeat every 4 weeks depending on ophthalmologic response (visual acuity or central subfield thickness assessment) (Wells 2015); refer to protocol and supplementary materials for additional dosage and administration details.

Endometrial cancer, recurrent or persistent (off-label use): IV: 15 mg/kg every 3 weeks (as monotherapy) until disease progression or unacceptable toxicity (Aghajanian 2011)

Hereditary hemorrhagic telangiectasia (off-label use): IV: 5 mg/kg every 2 weeks for 6 doses (Dupuis-Girod 2012). Additional data may be necessary to further define the role of bevacizumab in this condition.

Malignant pleural mesothelioma, unresectable (off-label use): IV: 15 mg/kg every 3 weeks (in combination with pemetrexed and cisplatin) for up to 6 cycles, followed by bevacizumab maintenance therapy at 15 mg/kg once every 3 weeks until disease progression or unacceptable toxicity (Zalcman 2016)

Soft tissue sarcoma, angiosarcoma, metastatic or locally advanced (off-label use): IV: 15 mg/kg every 3 weeks until disease progression or unacceptable toxicity (Agulnik 2013). Additional data may be necessary to further define the role of bevacizumab in this condition.

Dosing: Renal Impairment (Adult)

Renal impairment prior to treatment: There are no dosage adjustments provided in the manufacturer's labeling.

Renal toxicity during treatment:

Nephrotic syndrome: Discontinue bevacizumab.

Proteinuria ≥2 g/24 hours in the absence of nephrotic syndrome: Withhold bevacizumab until proteinuria <2 g/24 hours.

Dosing: Hepatic Impairment (Adult)

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Pediatric

(For additional information see "Bevacizumab (including biosimilars of bevacizumab): Pediatric drug information")

Note: Do not administer bevacizumab products until at least 28 days after surgery and the wound is fully healed.

Gliomas, recurrent or progressive (off-label use; based on limited data): Children and Adolescents: IV: 10 mg/kg every 2 weeks in combination with irinotecan (with or without temozolomide) (Kang 2008; Narayana 2010; Packer 2009; Parekh 2011). Additional data may be necessary to further define the role of bevacizumab in this condition.

Medulloblastoma, relapsed/refractory (off-label use; based on limited data): Children: IV: 10 mg/kg every 2 weeks in combination with irinotecan (with or without temozolomide; with or without vincristine) (Aguilera 2011; Aguilera 2013). Additional data may be necessary to further define the role of bevacizumab in this condition.

Solid tumors, refractory (off-label use; based on limited data): Children and Adolescents: IV: 5 to 10 mg/kg every 2 or 3 weeks (Benesch 2008). Additional data may be necessary to further define the role of bevacizumab in this condition.

Dosing: Renal Impairment (Pediatric)

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment (Pediatric)

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Adjustment for Toxicity

IV administration (systemic): There are no recommended dosage reductions.

Fistula (grade 4), tracheoesophageal fistula (any grade), fistula formation involving any internal organ: Discontinue bevacizumab.

Gastrointestinal perforation (any grade): Discontinue bevacizumab.

Heart failure: Discontinue bevacizumab.

Hemorrhage:

Grade 3 or 4: Discontinue bevacizumab.

Hemoptysis (recent history of ≥2.5 mL): Withhold bevacizumab.

Hypertension:

Hypertensive crisis: Discontinue bevacizumab.

Hypertensive encephalopathy: Discontinue bevacizumab.

Severe hypertension: Withhold bevacizumab if not controlled with medical management; resume when hypertension is controlled.

Infusion reaction:

Clinically insignificant (mild): Decrease infusion rate.

Clinically significant: Interrupt infusion; after symptoms resolve, resume at a decreased infusion rate.

Severe: Discontinue bevacizumab.

Posterior reversible encephalopathy syndrome (PRES): Discontinue bevacizumab.

Thromboembolic events:

Arterial thromboembolism (severe): Discontinue bevacizumab.

Venous thromboembolism (grade 4): Discontinue bevacizumab.

Wound healing complications (requiring medical intervention or necrotizing fasciitis): Discontinue bevacizumab.

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous [preservative free]:

Avastin: 100 mg/4 mL (4 mL); 400 mg/16 mL (16 mL)

Generic Equivalent Available (US)

No

Dosage Forms Considerations

Bevacizumab-awwb (Mvasi) is approved as a biosimilar to bevacizumab (Avastin).

Product Availability

Mvasi (bevacizumab-awwb): FDA approved September 2017; anticipated availability is currently unknown. Mvasi has been approved as a biosimilar, not as an interchangeable product. Consult the prescribing information for additional information.

Administration

IV: Infuse the initial dose over 90 minutes. The second infusion may be administered over 60 minutes if the initial infusion is well tolerated. The third and subsequent infusions may be administered over 30 minutes if the 60-minute infusion is well tolerated. After tolerance at the 90-, 60-, and 30-minute infusion rates has been established, some institutions use an off-label 10-minute infusion rate (0.5 mg/kg/minute) in adults for bevacizumab dosed at 5 mg/kg (Reidy 2007). In a study evaluating the safety of the 0.5 mg/kg/minute infusion rate, proteinuria, and hypertension incidences were not increased with the shorter infusion time (Shah 2013). Do not administer with dextrose solutions.

Monitor closely during the infusion for signs/symptoms of an infusion reaction. Decrease infusion rate for mild (clinically insignificant) infusion reaction; interrupt infusion for clinically significant infusion reaction (after symptoms resolve, resume at a decreased infusion rate); discontinue bevacizumab for severe infusion reaction.

Intravitreal injection (off-label use/route): Adequate local anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure.

Use

Cervical cancer, persistent/recurrent/metastatic (Avastin [bevacizumab], Mvasi [bevacizumab-awwb; biosimilar]): Treatment of persistent, recurrent, or metastatic cervical cancer (in combination with paclitaxel and either cisplatin or topotecan).

Colorectal cancer, metastatic (Avastin, Mvasi): First- or second-line treatment of metastatic colorectal cancer (CRC) (in combination with fluorouracil-based chemotherapy); second-line treatment of metastatic CRC (in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy) after progression on a first-line treatment containing bevacizumab.

Limitations of use: Not indicated for the adjuvant treatment of colon cancer.

Glioblastoma, recurrent (Avastin): Treatment of recurrent glioblastoma

Glioblastoma, progressive (Mvasi): Treatment of glioblastoma (as a single agent) in patients with progressive disease

Non-small cell lung cancer, nonsquamous (Avastin, Mvasi): First-line treatment of unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer (NSCLC) (in combination with carboplatin and paclitaxel).

Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-resistant recurrent) (Avastin): Treatment of platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with paclitaxel, doxorubicin [liposomal], or topotecan) in patients who received no more than 2 prior chemotherapy regimens.

Ovarian (epithelial), fallopian tube, or primary peritoneal cancer (platinum-sensitive recurrent) (Avastin): Treatment of platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine and then followed by single-agent bevacizumab).

Renal cell carcinoma, metastatic (Avastin, Mvasi): Treatment of metastatic renal cell carcinoma (RCC) (in combination with interferon alfa).

Use: Off-Label

Age-related macular degeneration; Breast cancer, metastatic; Diabetic macular edema; Endometrial cancer, recurrent or persistent; Gliomas (recurrent or progressive) (pediatrics); Hereditary hemorrhagic telangiectasia; Malignant pleural mesothelioma (unresectable); Medulloblastoma (relapsed or refractory); Soft tissue sarcoma, angiosarcoma; Soft tissue sarcoma, hemangiopericytoma; Solid tumors, refractory (pediatrics)

Medication Safety Issues
Sound-alike/look-alike issues:

Avastin may be confused with Astelin

Bevacizumab may be confused with bevacizumab-awwb, bezlotoxumab, brentuximab, cetuximab, ranibizumab, riTUXimab

High alert medication:

This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.

International issues:

Avastin [US, Canada, and multiple international markets] may be confused with Avaxim, a brand name for hepatitis A vaccine [Canada and multiple international markets]

Adverse Reactions

Percentages reported as monotherapy and as part of combination chemotherapy regimens. Some studies only reported hematologic toxicities grades ≥4 and nonhematologic toxicities grades ≥3.

>10%:

Cardiovascular: Hypertension (19% to 42%), venous thromboembolism (secondary: 21%; with oral anticoagulants), peripheral edema (15%), hypotension (7% to 15%), venous thromboembolism (8% to 14%), arterial thrombosis (6%)

Central nervous system: Fatigue (33% to 82%), pain (8% to 62%), headache (22% to 49%), dizziness (13% to 26%), insomnia (21%), taste disorder (14% to 21%), peripheral sensory neuropathy (17% to 18%), anxiety (17%), myasthenia (13%)

Dermatologic: Alopecia (6% to 32%), exfoliative dermatitis (23%), palmar-plantar erythrodysesthesia (11%), xeroderma (7%)

Endocrine & metabolic: Ovarian failure (34%), hyperglycemia (26% to 31%), hypomagnesemia (24% to 27%), weight loss (15% to 21%), hyponatremia (17% to 19%), hypoalbuminemia (11% to 16%), hypocalcemia (12%)

Gastrointestinal: Nausea (72%), abdominal pain (33% to 61%), vomiting (33% to 52%), anorexia (35% to 43%), constipation (40%), diarrhea (21% to 39%), decreased appetite (34% to 35%), stomatitis (15% to 33%), gastrointestinal hemorrhage (19% to 24%), dyspepsia (17% to 24%), mucosal inflammation (13% to 15%)

Genitourinary: Proteinuria (4% to 36%; median onset: 5.6 months; median time to resolution: 6.1 months), urinary tract infection (22%), pelvic pain (14%)

Hematologic & oncologic: Thrombocytopenia (5% to 58%; grade 3/4: 40%), hemorrhage (40%; grades 3/4: ≤7%), leukopenia (grades 3/4: 37%), pulmonary hemorrhage (4% to 31%), neutropenia (12%; grades ≥3: 8% to 27%, grade 4: 27%), bruise (17%), lymphocytopenia (12%; grades 3/4: 6%)

Infection: Infection (55%; serious: 7% to 14%; pneumonia, catheter infection, or wound infection)

Neuromuscular & skeletal: Arthralgia (28% to 45%), myalgia (19% to 29%), limb pain (25%), back pain (12% to 21%), dysarthria (8% to 14%)

Renal: Increased serum creatinine (13% to 16%)

Respiratory: Epistaxis (17% to 55%), upper respiratory tract infection (40% to 47%), cough (26% to 30%), dyspnea (25% to 30%), allergic rhinitis (17%), oropharyngeal pain (16%), sinusitis (7% to 15%), nasal sign & symptoms (mucosal disorder: 14%), rhinitis (3% to >10%)

Miscellaneous: Postoperative wound complication (including dehiscence, 1% to 15%)

1% to 10%:

Cardiovascular: Thrombosis (8% to 10%), deep vein thrombosis (6% to 9%), chest pain (8%), intra-abdominal thrombosis (venous, grades 3/4: 3%), syncope (grades 3/4: 3%), left ventricular dysfunction (grades 3/4: 1%), pulmonary embolism (1%)

Central nervous system: Voice disorder (5% to 13%)

Dermatologic: Nail disease (10%), dermal ulcer (6%), cellulitis (grades 3/4: 3%), acne vulgaris (1%)

Endocrine & metabolic: Dehydration (grades 3/4: 4% to 10%), hyperkalemia (9%), hypokalemia (grades 3/4: 7%)

Gastrointestinal: Hemorrhoids (8%), xerostomia (4% to 7%), gingival hemorrhage (minor, 2% to 7%), rectal pain (6%), colitis (1% to 6%), intestinal obstruction (grades 3/4: 4%), gastrointestinal perforation (≤3%), gastroesophageal reflux disease (2%), gingivitis (2%), oral mucosa ulcer (2%), gastrointestinal fistula (≤2%), gastritis (1%), gingival pain (1%)

Genitourinary: Vaginal hemorrhage (4%)

Hematologic & oncologic: Febrile neutropenia (5%), neutropenic infection (grades 3/4: 5%), hemorrhage (CNS; 5%)

Hepatic: Increased serum AST (15%)

Infection: Abscess (tooth, 2%)

Neuromuscular & skeletal: Weakness (grades 3/4: 10%), neck pain (9%)

Ophthalmic: Blurred vision (2%)

Otic: Tinnitus (2%), deafness (1%)

Respiratory: Rhinorrhea (10%), nasal congestion (8%), pneumonitis (grades 3/4: 5%)

Miscellaneous: Fistula (gastrointestinal-vaginal; 8%), fistula (anal; 6%), infusion related reaction (<3%), fistula (≤2%)

<1%, postmarketing, and/or case reports: Anaphylaxis, anastomotic ulcer, angina pectoris, antibody development (anti-bevacizumab and neutralizing), bladder fistula, bronchopleural fistula, cerebral infarction, conjunctival hemorrhage, endophthalmitis (infectious and sterile), eye discomfort, eye pain, fistula of bile duct, fulminant necrotizing fasciitis, gallbladder perforation, gastrointestinal ulcer, hemolytic anemia (microangiopathic; when used in combination with sunitinib), hemoptysis, hemorrhagic stroke, hypersensitivity, hypertensive crisis, hypertensive encephalopathy, increased intraocular pressure, inflammation of anterior segment of eye (toxic anterior segment syndrome) (Sato 2010), intestinal necrosis, intraocular inflammation (iritis, vitritis), mesenteric thrombosis, myocardial infarction, nasal septum perforation, nephrotic syndrome, ocular hyperemia, osteonecrosis of the jaw, pancytopenia, permanent vision loss, polyserositis, pulmonary hypertension, rectal fistula, renal failure, renal fistula, renal thrombotic microangiopathy, retinal detachment, retinal hemorrhage, reversible posterior leukoencephalopathy syndrome, sepsis, tracheoesophageal fistula, transient ischemic attacks, vaginal fistula, visual disturbance, vitreous hemorrhage, vitreous opacity

Contraindications

There are no contraindications listed in the manufacturer's US labeling.

Canadian labeling: Hypersensitivity to bevacizumab, any component of the formulation, Chinese hamster ovary cell products or other recombinant human or humanized antibodies; untreated CNS metastases

Warnings/Precautions

Concerns related to adverse effects:

• Gastrointestinal perforation/fistula: [US Boxed Warning]: GI perforation, (sometimes fatal) in patients receiving bevacizumab products ranges from 0.3% to 3%; discontinue bevacizumab products in patients with GI perforation. A higher incidence of GI perforation is associated with a history of prior pelvic radiation. Most cases of GI perforation occurred within 50 days of the first bevacizumab dose. Perforation may be complicated by intra-abdominal abscess, fistula formation, and/or diverting ostomy requirement. Serious fistulae (including tracheoesophageal, bronchopleural, biliary, vaginal, renal, and bladder fistulas) have been reported at a higher incidence in patients receiving bevacizumab products (compared to patients receiving chemotherapy), with the highest incidence occurring in patients with cervical cancer. Most fistulae occurred within 6 months of the first bevacizumab dose. Patients who develop gastrointestinal vaginal fistula may also have bowel obstruction which requires surgical intervention and diverting ostomy. Avoid bevacizumab products in patients with ovarian cancer with evidence of recto-sigmoid involvement (by pelvic examination) or bowel involvement (on CT scan), or clinical symptoms of bowel obstruction. Discontinue in patients who develop gastrointestinal perforation, tracheoesophageal fistula, any grade 4 fistula, or fistula formation involving any internal organ.

• Heart failure: In a scientific statement from the American Heart Association, bevacizumab has been determined to be an agent that may either cause reversible direct myocardial toxicity or exacerbate underlying myocardial dysfunction (magnitude: moderate/major) (AHA [Page 2016]). Bevacizumab is not indicated for use in combination with anthracycline-based chemotherapy. The incidence of grade ≥3 left ventricular dysfunction was higher in patients receiving bevacizumab with chemotherapy compared to patients who received chemotherapy alone (1% vs 0.6%). Among patients who received prior anthracycline therapy, the incidence of HF was higher in patients receiving bevacizumab with chemotherapy, compared to patients who received chemotherapy alone (4% vs 0.6%). In previously untreated patients with hematologic malignancy, the incidence of HF and left ventricular ejection fraction (LVEF) decline were increased in patients receiving bevacizumab with anthracycline-based chemotherapy (compared to patients receiving anthracycline-based chemotherapy alone). The proportion of patients with a LVEF decline (from baseline) of ≥20% or a decline from baseline of 10% to <50%, was higher in patients receiving bevacizumab with chemotherapy compared to patients receiving chemotherapy alone (10% vs 5%). Time to onset of left ventricular dysfunction or HF was 1 to 6 months after the first bevacizumab dose in most patients; HF resolved in nearly two-thirds of patients. Discontinue bevacizumab products in patients who develop HF.

• Hemorrhage: [US Boxed Warning]: Severe or fatal hemorrhage, including hemoptysis, gastrointestinal bleeding, hematemesis, central nervous system hemorrhage, epistaxis, and vaginal bleeding occur up to 5-fold more frequently in patients receiving bevacizumab products. Do not administer bevacizumab products to patients with a recent history of hemoptysis (≥2.5 mL blood). Discontinue in patients who develop grade 3 to 4 hemorrhage. Serious or fatal pulmonary hemorrhage has been reported in nearly one-third of patients receiving bevacizumab plus chemotherapy for non-small cell lung cancer (NSCLC) with squamous cell histology (not an FDA-approved indication), as well as a small portion of NSCLC with nonsquamous histology; while no cases occurred in patients receiving chemotherapy alone. Minor hemorrhages, including grade 1 epistaxis may commonly occur.

• Hypertension: Bevacizumab may cause and/or worsen hypertension. The incidence of severe hypertension in increased with bevacizumab products. Manage hypertension with antihypertensive therapy. Monitor BP every 2 to 3 weeks during bevacizumab treatment and regularly after discontinuation if bevacizumab-induced hypertension occurs or worsens. Withhold bevacizumab treatment in patients with severe hypertension that is uncontrolled with medical management (resume bevacizumab after blood pressure is controlled). Discontinue bevacizumab products in patients who experience a hypertensive crisis or hypertensive encephalopathy.

• Infusion reactions: Infusion reactions (eg, hypertension, hypertensive crisis [associated with neurologic signs/symptoms], wheezing, oxygen desaturation, hypersensitivity [grade 3], chest pain, rigors, headache, diaphoresis) may occur with the first infusion (uncommon); severe reactions were rare. Decrease the infusion rate for mild/clinically insignificant infusion reactions. Interrupt infusion for clinically significant infusion reactions and consider resuming at a slower rate following resolution. Discontinue bevacizumab for severe infusion reaction and administer appropriate medical therapy (eg, epinephrine, corticosteroids, IV antihistamines, bronchodilators, and/or oxygen).

• Mortality: Bevacizumab, in combination with chemotherapy (or biologic therapy), is associated with an increased risk of treatment-related mortality; a higher risk of fatal adverse events was identified in a meta-analysis of 16 trials in which bevacizumab was used for the treatment of various cancers (breast cancer, colorectal cancer, NSCLC, pancreatic cancer, prostate cancer, and renal cell cancer) and compared to chemotherapy alone (Ranpura 2011).

• Necrotizing fasciitis: Cases of necrotizing fasciitis, including fatalities, have been reported in patients receiving bevacizumab, usually secondary to wound healing complications, GI perforation or fistula formation. Discontinue in patients who develop necrotizing fasciitis.

• Ocular adverse events: Serious eye infections and vision loss due to endophthalmitis have been reported from intravitreal administration (off-label use/route).

• Osteonecrosis of the jaw (ONJ): According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), medication-related osteonecrosis of the jaw (MRONJ) has been associated with bisphosphonates and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy. Antiangiogenic agents, when given concomitantly with antiresorptive agents, are associated with an increased risk of ONJ. Other risk factors for MRONJ include dentoalveolar surgery (eg, tooth extraction, dental implants), preexisting inflammatory dental disease, and concomitant corticosteroid use. The AAOMS suggests that if medically permissible, initiation of antiangiogenic agents for cancer therapy should be delayed until optimal dental health is attained (if extractions are required, antiangiogenesis therapy should delayed until the extraction site has mucosalized or until after adequate osseous healing). Once antiangiogenic therapy for oncologic disease is initiated, procedures that involve direct osseous injury and placement of dental implants should be avoided. Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). Cases of non-mandibular ONJ has also been reported in pediatric patients who have received bevacizumab (bevacizumab is not approved for use in pediatric patients).

• Ovarian failure: In premenopausal women with solid tumors receiving adjuvant therapy, the incidence of ovarian failure was 34% for bevacizumab with chemotherapy versus 2% for chemotherapy alone. Recovery of ovarian function (resumption of menses, positive serum β-HCG pregnancy test, or FSH level <30 mIU/mL) at all time points in the post-treatment period after bevacizumab discontinuation was demonstrated in approximately one-fifth of females who received bevacizumab. The long-term effects of bevacizumab on fertility are unknown. Females of reproductive potential should be informed of the potential risk of ovarian failure prior to bevacizumab initiation.

• Posterior reversible encephalopathy syndrome: Cases of posterior reversible encephalopathy syndrome (PRES) have been reported. Symptoms (which include headache, seizure, confusion, lethargy, blindness and/or other vision, or neurologic disturbances) may occur from 16 hours to 1 year after treatment initiation. PRES may also be associated with mild to severe hypertension. MRI is necessary for confirmation of PRES diagnosis. Discontinue bevacizumab products in patients who develop PRES. Resolution of symptoms usually occurs within days after discontinuation; however, neurologic sequelae may remain. The safety of treatment reinitiation after PRES is not known.

• Proteinuria/nephrotic syndrome: Bevacizumab products are associated with an increased incidence and severity of proteinuria. Grade 3 (urine dipstick 4+ or >3.5 g protein/24 hours) and grade 4 (nephrotic syndrome) proteinuria have occurred in clinical studies. The overall incidence of all grades of proteinuria in one study was 20%. The median onset of proteinuria was 5.6 months (range: 0.5 to 37 months) after bevacizumab initiation and the median time to resolution was ~6 months. Proteinuria remained unresolved in 40% of patients after median follow-up of 11.2 months and required bevacizumab discontinuation in nearly one-third of patients. A pooled analysis from 7 studies found that 5% of patients receiving bevacizumab products in combination with chemotherapy experienced grades 2 to 4 proteinuria (urine dipstick 2+ or >1 g protein/24 hours or nephrotic syndrome), which resolved in nearly three-fourths of patients; bevacizumab was reinitiated in 42% of patients, although nearly half of patients who reinitiated experienced recurrent grades 2 to 4 proteinuria. Nephrotic syndrome has occurred (rarely) in patients receiving bevacizumab, sometimes with fatal outcome. In some cases, kidney biopsy of patients with proteinuria demonstrated findings consistent with thrombotic microangiopathy. A large retrospective analysis comparing bevacizumab with chemotherapy to chemotherapy alone found higher rates of serum creatinine elevations (1.5 to 1.9 times baseline) in patients who received bevacizumab; serum creatinine did not return to baseline in approximately one-third of patients who received bevacizumab. Monitor proteinuria (by serial dipstick urine analysis) for proteinuria development or worsening of proteinuria throughout bevacizumab therapy. Further assess with a 24-hour urine collection for ≥2+ urine dipstick readings. Withhold bevacizumab for proteinuria ≥2 g/24 hours; resume when <2 g/24 hours. Discontinue bevacizumab products in patients who develop nephrotic syndrome. Urine protein/creatinine ratio (UPCR) does not appear to correlate with 24-hour urine protein.

• Thromboembolism: Bevacizumab products are associated with an increased incidence of arterial thromboembolic events (ATE), including cerebral infarction, stroke, MI, TIA, angina, and other ATEs, when used in combination with chemotherapy. The highest incidence of ATE occurred in patients with glioblastoma. History of ATE, diabetes, or ≥65 years of age may present an even greater risk. Although patients with cancer are already at risk for VTE, a meta-analysis of 15 controlled trials has demonstrated an increased risk for VTE in patients who received bevacizumab (Nalluri 2008). Patients receiving bevacizumab plus chemotherapy had a higher incidence of grade 3 or higher VTE compared to those patients who received chemotherapy alone. Discontinue bevacizumab in patients with severe ATE or grade 4 VTE, including pulmonary embolism.

• Wound healing complications: [US Boxed Warning]: The incidence of wound healing and surgical complications, including serious and fatal complications, is increased in patients receiving bevacizumab products; discontinue in patients who develop wound healing complications that require medical intervention. Withhold bevacizumab products at least 28 days prior to elective surgery. Do not administer bevacizumab products for at least 28 days after surgery and until the surgical wound is fully healed. In a controlled study in which bevacizumab was not administered within 28 days of major surgical procedures, the incidence of wound healing complications (including serious/fatal complications) was higher in patients with mCRC who underwent surgery while receiving bevacizumab compared to patients who did not receive bevacizumab. In a controlled clinical study in patients with relapsed or recurrent glioblastoma, the incidence of wound healing events was higher in patients who received bevacizumab compared to patients who did not receive bevacizumab. In a retrospective review of central venous access device placements (a minor procedure), a greater risk of wound dehiscence was observed when port placement and bevacizumab administration were separated by <14 days (Erinjeri 2011). If possible, it may be more appropriate to wait until at least 6 to 8 weeks after bevacizumab discontinuation for major surgical procedures (Cortes 2012; Gordon 2009).

Disease-related concerns:

• Renal impairment: An increase in diastolic and systolic blood pressures were noted in a retrospective review of patients with renal insufficiency (CrCl ≤60 mL/minute) who received bevacizumab for renal cell cancer (Gupta 2011).

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Patients ≥65 years of age have an increased incidence of arterial thrombotic events.

Metabolism/Transport Effects

None known.

Drug Interactions

(For additional information: Launch drug interactions program)

Anthracyclines: Bevacizumab may enhance the cardiotoxic effect of Anthracyclines. Risk X: Avoid combination

BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. Risk X: Avoid combination

Bisphosphonate Derivatives: Angiogenesis Inhibitors (Systemic) may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased. Risk C: Monitor therapy

Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents. Risk C: Monitor therapy

CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. Risk C: Monitor therapy

Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Risk X: Avoid combination

Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased Risk X: Avoid combination

Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents. Risk C: Monitor therapy

SORAfenib: Bevacizumab may enhance the adverse/toxic effect of SORAfenib. Specifically, the risk for hand-foot skin reaction may be increased. Risk C: Monitor therapy

SUNItinib: May enhance the adverse/toxic effect of Bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of SUNItinib. Risk X: Avoid combination

Pregnancy Implications

Based on findings in animal reproduction studies and on the mechanism of action, bevacizumab may cause fetal harm if administered to a pregnant woman. Information from postmarketing reports following exposure in pregnancy is limited. Women of reproductive potential should use effective contraception during therapy and for 6 months following the last bevacizumab dose. Bevacizumab treatment may also increase the risk of ovarian failure and impair fertility; long term effects on fertility are not known.

Breast-Feeding Considerations

It is not known if bevacizumab is present in breast milk. Immunoglobulins are excreted in breast milk, and it is assumed that bevacizumab may appear in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment and for 6 months following the last dose of bevacizumab products.

Monitoring Parameters

Monitor for proteinuria/nephrotic syndrome with urine dipstick; collect 24-hour urine in patients with ≥2+ reading. Monitor blood pressure every 2 to 3 weeks; more frequently if hypertension develops during therapy; continue to monitor blood pressure after discontinuing due to bevacizumab-induced hypertension. Monitor closely during the infusion for signs/symptoms of an infusion reaction. Monitor for signs/symptoms of gastrointestinal perforation or fistula (including abdominal pain, constipation, vomiting, and fever), bleeding (including epistaxis, hemoptysis, gastrointestinal, and/or CNS bleeding), and thromboembolism (arterial and venous).

AMD (off-label use): Monitor intraocular pressure and retinal artery perfusion. Monitor for signs/symptoms of infectious endophthalmitis and retinal detachment (AAO 2011).

Diabetic macular edema (off-label use): Monitor visual acuity, central subfield thickness, and intraocular pressure; monitor for signs/symptoms of infectious endophthalmitis, cataracts, and retinal detachment (AAO 2016).

Hereditary hemorrhagic telangiectasia (off-label use): Cardiac output measurements and liver radiologic response (via ultrasound and hepatic CT exams) prior to initial treatment and at 3 and 6 months following the first dose.

Mechanism of Action

Bevacizumab is a recombinant, humanized monoclonal antibody which binds to, and neutralizes, vascular endothelial growth factor (VEGF), preventing its association with endothelial receptors, Flt-1 and KDR. VEGF binding initiates angiogenesis (endothelial proliferation and the formation of new blood vessels). The inhibition of microvascular growth is believed to retard the growth of all tissues (including metastatic tissue).

Pharmacodynamics/Kinetics

Distribution: CV% central volume: 2.9 (22%) L

Half-life elimination:

IV:

Pediatric patients (age: 1 to 21 years): Median: 11.8 days (range: 4.4 to 14.6 days) (Glade Bender 2008)

Adults: ~20 days (range: 11 to 50 days)

Intravitreal: ~5 to 10 days (Bakri 2007; Krohne 2008)

Pharmacodynamics/Kinetics: Additional Considerations

Gender: Men had a higher clearance and larger volume of distribution in the central compartment when compared with women. There is no evidence that this difference decreases the efficacy of bevacizumab in men.

Tumor burden: Patients with a higher tumor burden had a higher clearance of bevacizumab compared with patients who had a tumor burden below the median. There is no evidence suggesting that this difference leads to decreased efficacy.

Pricing: US

Solution (Avastin Intravenous)

100 mg/4 mL (4 mL): $933.00

400 mg/16 mL (16 mL): $3,732.00

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Avastin (AE, AR, AT, AU, BB, BE, BG, BH, BR, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, ID, IE, IL, IS, IT, JO, JP, KR, KW, LB, LK, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN);
  • Avastyn (UA);
  • Bevastim (BD);
  • Bivastin (BD)
Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. J Clin Oncol. 2012;30(17):2039-2045. [PubMed 22529265]
  2. Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10-16. [PubMed 26271155]
  3. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259-2265. [PubMed 21537039]
  4. Aguilera DG, Goldman S, Fangusaro J. Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. Pediatr Blood Cancer. 2011;56:491-494. doi: 10.1002/pbc.22868. [PubMed 21072819]
  5. Aguilera D, Mazewskli C, Fangusaro J, et al. Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Childs Nerv Syst. 2013;29:589-596. doi: 10.1007/s00381-012-2013-4. [PubMed 23296323]
  6. Agulnik M, Yarber JL, Okuno SH, et al. An Open-Label, Multicenter, Phase II Study of Bevacizumab for the Treatment of Angiosarcoma and Epithelioid Hemangioendotheliomas. Ann Oncol. 2013;24(1):257-263. [PubMed 22910841]
  7. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. J Clin Oncol. 2009;27(20):3385-3390. [PubMed 19414665]
  8. American Academy of Ophthalmology. Diabetic Retinopathy. https://www.aao.org/preferred-practice-pattern/diabetic-retinopathy-ppp-updated-2016. Accessed November 14, 2017.
  9. American Academy of Ophthalmology. Age-related macular degeneration preferred practice pattern guidelines. http://one.aao.org/preferred-practice-pattern/agerelated-macular-degeneration-ppp--september-200. Updated 2011. Accessed May 12, 2014.
  10. Avastin (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; December 2017.
  11. Avastin (bevacizumab) [product monograph]. Mississauga, ON, Canada: Hoffmann-La Roche; February 2017.
  12. Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-Foot Skin Reaction Increases With Cumulative Sorafenib Dose and With Combination Anti-Vascular Endothelial Growth Factor Therapy. Clin Cancer Res. 2009;15(4):1411-1416. [PubMed 19228742]
  13. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology, 2007;114(5):855-859. [PubMed 17467524]
  14. Bansal N and Hoffman M. Bladder Perforation in a Patient With Recurrent Epithelial Ovarian Cancer After Treatment With Bevacizumab. Gynecol Oncol. 2011;120(2):313-314. [PubMed 21055796]
  15. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004-3011. [PubMed 23835708]
  16. Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol. 2008;19(4):807-813. doi: 10.1093/annonc/mdm510. [PubMed 18056650]
  17. Bracarda S, Bellmunt J, Melichar B, et al. Overall Survival in Patients With Metastatic Renal Cell Carcinoma Initially Treated With Bevacizumab Plus Interferon-α2a and Subsequent Therapy With Tyrosine Kinase Inhibitors: A Retrospective Analysis of the Phase III AVOREN Trial. BJU Int. 2011;107(2):214-219. [PubMed 20942831]
  18. Burger RA, Brady MF, Bookman MA, et al. Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 2011;365(26):2473-2483. [PubMed 22204724]
  19. Burger RA, Sill MW, Monk BJ, et al. Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171. [PubMed 18024863]
  20. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer. J Clin Oncol. 2007;25(33):5180-5186. [PubMed 18024865]
  21. Chakravarthy U, Harding SP, Rogers CA, et al; IVAN study investigators. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267. [PubMed 23870813]
  22. Christodoulou C, Pervena A, Klouvas G, et al. Combination of Bisphosphonates and Antiangiogenic Factors Induces Osteonecrosis of the Jaw More Frequently Than Bisphosphonates Alone. Oncology. 2009;76(3):209-211. [PubMed 19212145]
  23. Cloughesy TF, Prados MD, Wen PY, et al. A Phase II, Randomized, Non-Comparative Clinical Trial of the Effect of Bevacizumab (BV) Alone or in Combination With Irinotecan (CPT) on 6-Month Progression Free Survival (PFS6) in Recurrent, Treatment-Refractory Glioblastoma (GBM). J Clin Oncol. 2008;26(supp):2010B [abstract 2010b from 2008 ASCO Annual Meeting].
  24. Coleman RL, Brady MF, Herzog TJ, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). Scientific Plenary #3 Presented at the 2015 Annual Meeting for Women's Cancers. March 28, 2015. Chicago, IL.
  25. Cortés J, Caralt M, Delaloge S, et al. Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. Eur J Cancer. 2012;48(4):475-481. [PubMed 22196033]
  26. Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013;60(7):1073-1082. [PubMed 23512831]
  27. Dupuis LL, Boodhan S, Sung L; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57(2):191-198. [PubMed 21465637]
  28. Dupuis-Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA. 2012;307(9):948-955. [PubMed 22396517]
  29. Erinjeri JP, Fong AJ, Kemeny NE, et al, “Timing of Administration of Bevacizumab Chemotherapy Affects Wound Healing After Chest Wall Port Placement,” Cancer, 2011, 117(6):1296-301. [PubMed 21381016]
  30. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab Plus Interferon Alfa-2a for Treatment of Metastatic Renal Cell Carcinoma: A Randomised, Double-Blind Phase III Trial. Lancet. 2007;370(9605):2103-2111. [PubMed 18156031]
  31. Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol. 2008;26(24):4037-4038. [PubMed 18711196]
  32. Feldman DR, Baum MS, Ginsberg MS, et al. Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2009;27(9):1432-1439. [PubMed 19224847]
  33. Feldman DR, Ginsberg MS, Baum M, et al. Phase I Trial of Bevacizumab Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma. J Clin Oncol. 2008;26(supp):5100 [abstract 5100 from 2008 ASCO Annual Meeting].
  34. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740. [PubMed 1972097]
  35. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. J Clin Oncol. 2008;26(3):399-405. [PubMed 18202416]
  36. Glusker P, Recht L, Lane B. Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab. N Engl J Med. 2006;354(9):980-982. [PubMed 16510760]
  37. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62(6):707-709. [PubMed 19461291]
  38. Greuter S, Schmid F, Ruhstaller T, et al. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008;19(12):2091-2092. [PubMed 18977851]
  39. Gray R, Bhattacharya S, Bowden C, et al. Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer. J Clin Oncol. 2009;27(30):4966-4972. [PubMed 19720913]
  40. Gupta S, Parsa VB, Heilbrun LK, et al. Safety and Efficacy of Molecularly Targeted Agents in Patients With Metastatic Kidney Cancer With Renal Dysfunction. Anticancer Drugs. 2011;22(8):794-800. [PubMed 21799472]
  41. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789. [PubMed 28759346]
  42. Johnson DH, Fehrenbacher L, Novotny WF, et al, “Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer,” J Clin Oncol, 2004, 22(11):2184-91. [PubMed 15169807]
  43. Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. 2008;89:113-118. doi: 10.1007/s11060-008-9599-0. [PubMed 18438609]
  44. Kreisl TN, Kim L, Moore K, et al. Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma. J Clin Oncol. 2009;27(5):740-745. [PubMed 19114704]
  45. Krohne TU, Eter N, Holz FG, et al. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146(4):508-512. [PubMed 18635152]
  46. Leighl NB, Bennouna J, Yi J, et al. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer. 2011;104(3):413-418. [PubMed 21245868]
  47. Leighl NB, Zatloukal P, Mezger J, et al. Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL). J Thorac Oncol. 2010;5(12):1970-1976. [PubMed 20978447]
  48. Lou E, Turner S, Sumrall A, et al, “Bevacizumab-Induced Reversible Posterior Leukoencephalopathy Syndrome and Successful Retreatment in a Patient With Glioblastoma,” J Clin Oncol, 2011, 29(28):e739-42. [PubMed 21900098]
  49. Martin DF, Maguire MG, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398. [PubMed 22555112]
  50. Masters GA, Temin S, Azzoli CG, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015;33(30):3488-3515. [PubMed 26324367]
  51. Miles D, Chan A, Dirix LY, et al, "Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer,” J Clin Oncol, 2010, 28(20):3239-47. [PubMed 20498403]
  52. Miller KD, "E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast Cancer," Clin Breast Cancer, 2003, 3(6):421-2. [PubMed 12636887]
  53. Miller KD, Chap LI, Holmes FA, et al, "Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer," J Clin Oncol, 2005, 23(4):792-9. [PubMed 15681523]
  54. Miller K, Wang M, Gralow J, et al, “Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer,” N Engl J Med, 2007, 357(26):2666-76. [PubMed 18160686]
  55. Monk BJ, Choi DC, Pugmire G, et al, “Activity of Bevacizumab (rhuMAB VEGF) in Advanced Refractory Epithelial Ovarian Cancer,” Gynecol Oncol, 2005, 96(3):902-5. [PubMed 15721449]
  56. Monk BJ, Sill MW, Burger RA, et al, "Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study," J Clin Oncol, 2009, 27(7):1069-74. [PubMed 19139430]
  57. Mvasi (bevacizumab-awwb) [prescribing information]. Thousand Oaks, CA: Amgen Inc; September 2017. [PubMed 19139430]
  58. Nalluri SR, Chu D, Keresztes R, et al, “Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-Analysis,” JAMA, 2008, 300(19): 2277-85. [PubMed 19017914]
  59. Narayana A, Kunnakkat S, Chacko-Mathew J, et al. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncology. 2010;12(9):985-990. doi: 10.1093/neuonc/noq033. [PubMed 20363768]
  60. Ozcan C, Wong SJ, and Hari P, “Reversible Posterior Leukoencephalopathy Syndrome and Bevacizumab,” N Engl J Med, 2006, 354(9):981-2. [PubMed 16514715]
  61. Packer RJ, Jakacki R, Horn M, et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer. 2009;52:791-795. doi: 10.1002/pbc.21935. [PubMed 19165892]
  62. Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in Circulation. 2016;134(12):e261]. Circulation. 2016;134(6):e32-e69. doi: 10.1161/CIR.0000000000000426. [PubMed 27400984]
  63. Parekh C, Jubran R, Erdreich-Epstein A, et al. Treatment of children with recurrent high grade gliomas with a bevacizumab containing regimen. J Neurooncol. 2011;103: 673-680. doi: 10.1007/s11060-010-0444-x. [PubMed 21038110]
  64. Park MS, Patel SR, Ludwig JA, et al, “Activity of Temozolomide and Bevacizumab in the Treatment of Locally Advanced, Recurrent, and Metastatic Hemangiopericytoma and Malignant Solitary Fibrous Tumor,” Cancer, 2011, 117(21):4939-47. [PubMed 21480200]
  65. Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(34):4349-4357. [PubMed 24145346]
  66. Perren TJ, Swart AM, Pfisterer J, et al, “A Phase 3 Trial of Bevacizumab in Ovarian Cancer,” N Engl J Med, 2011, 365(26):2484-96. [PubMed 22204725]
  67. Polyzos A, Kalbakis K, Kentepozidis N, et al, “Salvage Treatment In Metastatic Breast Cancer With Weekly Paclitaxel and Bevacizumab,” Cancer Chemother Pharmacol, 2011, 68(1):217-23. [PubMed 20922389]
  68. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302-1308. [PubMed 24637997]
  69. Ranpura V, Hapani S, and Wu S, “Treatment-Related Mortality With Bevacizumab in Cancer Patients,” JAMA, 2011, 305(5):487-94. [PubMed 21285426]
  70. Reck M, von Pawel J, Zatloukal P, et al; BO17704 Study Group. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804-1809. [PubMed 20150572]
  71. Reck M, von Pawel J, Zatloukal P, et al, “Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAil,” J Clin Oncol, 2009, 27(8):1227-34. [PubMed 19188680]
  72. Reidy DL, Chung KY, Timoney JP, et al, “Bevacizumab 5 mg/kg Can be Infused Safely over 10 minutes,” J Clin Oncol, 2007, 25(19):2691-5. [PubMed 17602073]
  73. Rini BI, Halabi S, Rosenberg JE, et al, “Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206,” J Clin Oncol, 2008, 26(33):5422-8. [PubMed 18936475]
  74. Robert NJ, Dieras V, Glaspy J, et al, “RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab (B) for First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (MBC),” J Clin Oncol, 2009, 27(15s):1005 [abstract 1005 from 2009 ASCO Annual Meeting]
  75. Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270. [PubMed 27664248]
  76. Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031. [PubMed 25234529]
  77. Saltz LB, Clarke S, Díaz-Rubio E, et al, “Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy as First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study,” J Clin Oncol, 2008, 26(12):2013-9. [PubMed 18421054]
  78. Sandler A, Gray R, Perry MC, et al, “Paclitaxel-Carboplatin Alone or With Bevacizumab for Non-Small-Cell Lung Cancer,” N Engl J Med, 2006, 355(24):2542-50. [PubMed 17167137]
  79. Sane DC, Anton L, and Brosnihan KB, “Angiogenic Growth Factors and Hypertension,” Angengenesis, 2004, 7(3):193-201.
  80. Scappaticci FA, Skillings JR, Holden SN, et al, “Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated With Chemotherapy and Bevacizumab,” J Natl Cancer Inst, 2007, 99(16):1232-9. [PubMed 17686822]
  81. Shah SR, Gressett Ussery SM, Dowell JE, et al. Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. Ann Oncol. 2013;24(4):960-965. [PubMed 23175623]
  82. Stockler MR, Hilpert F, Friedlander M, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32(13):1309-1316. [PubMed 24687829]
  83. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743. [PubMed 24552320]
  84. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al, “Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme,” J Clin Oncol, 2007, 25(30):4722-9. [PubMed 17947719]
  85. Wagner AD, Thomssen C, Haerting J, et al, “Vascular-Endothelial-Growth-Factor (VEGF) Targeting Therapies for Endocrine Refractory or Resistant Metastatic Breast Cancer,” Cochrane Database Syst Rev, 2012, 7:CD008941. [PubMed 22786517]
  86. Wells JA, Glassman AR, Ayala AR, et al, “Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. Diabetic Retinopathy Clinical Research Network,” N Engl J Med. 2015;372(13):1193-1203. doi: 10.1056/NEJMoa1414264. [PubMed 25692915]
  87. Wick W, Gorlia T, Bendszus M, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954-1963. [PubMed 29141164]
  88. Yang JC, Haworth L, Sherry RM, et al, “A Randomized Trial of Bevacizumab, An Antivascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer,” N Engl J Med, 2003, 349(5):427-34. [PubMed 12890841]
  89. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial [Erratum in: Lancet. 2016;387(10026):e24]. Lancet. 2016;387(10026):1405-1414. [PubMed 26719230]
  90. Zhu J, Sharma DB, Gray SW, et al, “Carboplatin and Paclitaxel With vs Without Bevacizumab in Older Patients With Advanced Non-Small Cell Lung Cancer,” JAMA, 2012, 307(15):1593-601. [PubMed 22511687]
Topic 8683 Version 162.0